Meeting
2013 Gastrointestinal Cancers Symposium
A cost-effectiveness analysis of bevacizumab (BV) plus chemotherapy (CT) versus aflibercept (AFLI) plus CT in patients with metastatic colorectal cancer (mCRC) previously treated with BV.
Authors
Robert Morlock
Genentech
Robert Morlock , Elaine Yu , Joshua Ray
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Cancers of the Colon and Rectum
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Translational Research
Citation
J Clin Oncol 31, 2013 (suppl 4; abstr417)
DOI
10.1200/jco.2013.31.4_suppl.417
Abstract #
417
Poster Bd #
B29
Abstract Disclosures
Similar Posters
Poster
2021 Gastrointestinal Cancers Symposium
Is antiangiogenic therapy necessary for patients with metastatic colorectal cancer (mCRC) and mutation in the BRAF gene? Results of the systematic review and meta-analysis.
First Author: Mikhail Fedyanin
Poster
2014 ASCO Quality Care Symposium
Comparative effectiveness of antiangiogenesis inhibitors for second-line therapy of metastatic colorectal cancer.
First Author: Christina Xiaoyue Chen
Poster
2022 ASCO Gastrointestinal Cancers Symposium
BREAKWATER safety lead-in (SLI): Encorafenib + cetuximab (EC) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAFV600E) metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz
Poster
2021 Gastrointestinal Cancers Symposium
Cost-effectiveness of cetuximab + FOLFIRI versus bevacizumab + FOLFIRI in the first-line treatment of RAS wild-type metastatic colorectal cancer in China.
First Author: Ilse Van Oostrum